Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells
Metrics: PDF 879 views | Full Text 1091 views | ?
Austin R. Dosch1,2, Xizi Dai1,2, Alexander A. Gaidarski III1,2, Chanjuan Shi3, Jason A. Castellanos4, Michael N. VanSaun1,2, Nipun B. Merchant1,2 and Nagaraj S. Nagathihalli1,2
1Division of Surgical Oncology, Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
2Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
3Department of Pathology, Vanderbilt University School of Medicine, Nashville, TN, USA
4Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA
Nagaraj S. Nagathihalli, email: email@example.com
Keywords: pancreatic ductal adenocarcinoma; SRC kinase; E-cadherin; Dasatinib; epithelial-to-mesenchymal transition (EMT)
Received: October 18, 2018 Accepted: January 02, 2019 Published: February 01, 2019
The Src family of non-receptor tyrosine kinases are frequently activated in pancreatic ductal adenocarcinoma (PDAC), contributing to disease progression through downregulation of E-cadherin and induction of epithelial-to-mesenchymal transition (EMT). The purpose of this study was to examine the efficacy of Src kinase inhibition in restoring E-cadherin levels in PDAC. Immunohistochemical analysis of human PDAC samples showed Src activation is inversely correlated with E-cadherin levels. Protein and mRNA levels of E-cadherin, the gene expression of its various transcriptional repressors (Zeb1, Snail, Slug, LEF-1, TWIST), and changes in sub-cellular localization of E-cadherin/β-catenin in PDAC cells were characterized in response to treatment with the Src inhibitor, dasatinib (DST). DST repressed Slug mRNA expression, promoted E-cadherin transcription, and increased total and membranous E-cadherin/β-catenin levels in drug-sensitive PDAC cells (BxPC3 and SW1990), however no change was observed in drug-resistant PANC1 cells. BxPC3, PANC1, and MiaPaCa-2 flank tumor xenografts were treated with DST to examine changes in E-cadherin levels in vivo. Although DST inhibited Src phosphorylation in all xenograft models, E-cadherin levels were only restored in BxPC3 xenograft tumors. These results suggest that Src kinase inhibition reverses EMT in drug-sensitive PDAC cells through Slug-mediated repression of E-cadherin and identifies E-cadherin as potential biomarker for determining response to DST treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.